Literature DB >> 26494129

Adoption of a national antimicrobial guide (SWAB-ID) in the Netherlands.

Emelie C Schuts1, Caroline M van den Bosch2, Inge C Gyssens3,4,5, Bart-Jan Kullberg3, Maurine A Leverstein-van Hall6, Stephanie Natsch7, Fre Sebens8, Martha B Adams9, Richard Drew10, Jan M Prins11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26494129     DOI： 10.1007/s00228-015-1969-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  Quality assuring adult anti-microbial guidelines.

Authors:  Husayn Al Mahdy
Journal:  Int J Health Care Qual Assur       Date:  2012

2.  Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project.

Authors:  M Eccles; Z Clapp; J Grimshaw; P C Adams; B Higgins; I Purves; I Russell
Journal:  Qual Health Care       Date:  1996-03

3.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

4.  Relationship of antimicrobial control policies and hospital and infection control characteristics to antimicrobial resistance rates.

Authors:  Elaine L Larson; Dave Quiros; Tara Giblin; Susan Lin
Journal:  Am J Crit Care       Date:  2007-03       Impact factor: 2.228

Review 5.  Navigating the Web in search of resources on antimicrobial stewardship in health care institutions.

Authors:  Leonardo Pagani; Inge C Gyssens; Benedikt Huttner; Dilip Nathwani; Stephan Harbarth
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

6.  Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence.

Authors:  V Spoorenberg; J M Prins; E E Stobberingh; M E J L Hulscher; S E Geerlings
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-04       Impact factor: 3.267

7.  Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.

Authors:  Seung Soon Lee; Youngsu Kim; Doo Ryeon Chung
Journal:  J Infect       Date:  2010-11-03       Impact factor: 6.072

8.  Initial management of pneumonia and sepsis: factors associated with improved outcome.

Authors:  R Menéndez; A Torres; S Reyes; R Zalacain; A Capelastegui; J Aspa; L Borderías; J J Martín-Villasclaras; S Bello; I Alfageme; F R de Castro; J Rello; L Molinos; J Ruiz-Manzano
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

9.  [Optimalisation of the antibiotic policy in The Netherlands. XI. The national electronic antibiotic guide'SWAB-ID' for use in hospitals].

Authors:  M G A van Vonderen; I C Gyssens; N G Hartwig; B J Kullberg; M A Leverstein-van Hall; S Natsch; J M Prins
Journal:  Ned Tijdschr Geneeskd       Date:  2006-11-18

Review 10.  A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance.

Authors:  Brian G Bell; Francois Schellevis; Ellen Stobberingh; Herman Goossens; Mike Pringle
Journal:  BMC Infect Dis       Date:  2014-01-09       Impact factor: 3.090
View more
  1 in total

1.  Successful improvement of antibiotic prescribing at Primary Care in Andalusia following the implementation of an antimicrobial guide through multifaceted interventions: An interrupted time-series analysis.

Authors:  Rocío Fernández-Urrusuno; Carmen Marina Meseguer Barros; Regina Sandra Benavente Cantalejo; Elena Hevia; Carmen Serrano Martino; Aranzazu Irastorza Aldasoro; Juan Limón Mora; Antonio López Navas; Beatriz Pascual de la Pisa
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.